ArticleFrontiers in immunology2026
Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is a chronic autoimmune blistering disease predominantly affecting the elderly, with conventional immunosuppressive treatments often limited by insufficient efficacy and severe adverse effects. Emerging targeted therapies offer new opportunities, yet optimal treatment strategies remain to be defined. Herein, we report a case of BP in a 69-year-old woman with insufficient response to initial systemic corticosteroid therapy, successfully managed with a bridging targeted approach using abrocitinib and dupilumab. Initiation of abrocitinib (200 mg daily) resulted in rapid pruritus relief within 24 hours and cessation of new blister formation within 6 days. Symptom relapse and reinduction upon dose reduction and restoration suggested a dose-dependent therapeutic effect of abrocitinib. Dupilumab was subsequently introduced for long-term disease control, while abrocitinib was gradually tapered off. After more than six months of targeted therapy, sustained complete remission was achieved, with a favorable safety profile. Objective disease activity improved in parallel with clinical remission, with BPDAI decreasing from 120 at baseline to 0, pruritus NRS from 9 to 0, and peripheral eosinophil counts returning to the normal range during follow-up. Mechanistically, abrocitinib may rapidly suppress pruritus and inflammation through JAK1-dependent blockade of IL-4, IL-13, and IL-31 signaling. In contrast, dupilumab provides sustained disease control by inhibiting IL-4/IL-13-mediated Th2 responses, reducing eosinophilic inflammation and autoantibody production. This case highlights a complementary therapeutic strategy integrating rapid disease control with long-term immune modulation, suggesting that our bridging therapy may represent a rational and effective approach for patients with bullous pemphigoid with insufficient response to initial corticosteroid therapy, warranting further investigation in controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.